Pulmatrix

Pulmatrix Capital Expenditures

Capital Expenditures (CapEx) of Pulmatrix (PULM) as of Oct 17, 2026.

Capital Expenditures

0.00USD

Last updated:

Capital Expenditures (CapEx) of Pulmatrix is 2025 0.00 USD. Capital Expenditures (CapEx) of Pulmatrix was 2024 -398,000.00 USD. It decreases by % higher compared to the previous year.

The Pulmatrix Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-19,000.00 USD
Jan 1, 2019
-58,000.00 USD
Jan 1, 2020
-281,000.00 USD
Jan 1, 2021
-144,000.00 USD
Jan 1, 2022
-86,000.00 USD
Jan 1, 2023
-676,000.00 USD
Jan 1, 2024
-398,000.00 USD
Jan 1, 2025
0.00 USD
The Pulmatrix Capital Expenditures history
YEARCapital ExpendituresYoY
0.00USD-100.00%
-398,000.00USD-41.12%
-676,000.00USD+686.05%
-86,000.00USD-40.28%
-144,000.00USD-48.75%
-281,000.00USD+384.48%
-58,000.00USD+205.26%
-19,000.00USD-74.32%
-74,000.00USD-83.74%
-455,000.00USD+71.05%
-266,000.00USD+70.51%
-156,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pulmatrix Stock analysis

What does Pulmatrix do? Pulmatrix Inc is a clinical stage biotechnology company based in Lexington, Massachusetts, focused on developing inhaled therapeutic products for respiratory and other diseases. The company went public via an IPO on March 21, 2014, and currently employs two full-time staff members. Pulmatrix utilizes its proprietary dry powder delivery technology, iSPERSE, to create inhaled therapies designed for local or systemic drug delivery to the lungs. The iSPERSE platform enables the formulation of small or large molecule drugs into dry powder form, engineered to be small, dense particles with optimal dispersibility and airway delivery. This technology is compatible with various dry powder inhaler devices and supports a wide range of drug substances, including small molecules and biologics. Pulmatrix has several therapeutic candidates in development, including Pulmazole, PUR1800, PUR5700, PUR3000, and PUR4000. The company's website is www.pulmatrix.com. Pulmatrix operates within the pharmaceuticals sector of the health care industry, targeting serious respiratory conditions through innovative inhaled drug delivery solutions. Pulmatrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulmatrix stock

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Pulmatrix since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Pulmatrix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Pulmatrix

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Pulmatrix